Eli Lilly said last night it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation ...
With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...
When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients ...
Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...
Effective compliance now spans transaction eligibility, OPAIS synchronization, Medicaid exclusion validation, cost-report ...
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 ...
On December 29, 2025—just three days before the 340B Rebate Model Pilot Program (the Rebate Program) was set to begin—the U.S. District Court for the District of Maine issued an order granting a ...
Three health systems are suing CVS Health, alleging the company and its pharmacy subsidiaries diverted roughly $250 million in savings from the 340B Drug Pricing Program. The 340B program was ...
Nevada hospitals and clinics face challenges as drug manufacturers restrict access to a federal discount drug program, ...
Minnesota's 340B drug discount program faces scrutiny as small clinics struggle and large hospitals profit, sparking ...
A federal judge in Missouri has denied a request by AstraZeneca Pharmaceuticals LP to compel several nonparty hospitals and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results